First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years’ experience
Jing Hu,Li Zhang,Xin Zhao,Xu Liu,Liping Jing,Kang Zhou,Yuan Li,Yang Li,Jianping Li,Lei Ye,Guangxin Peng,Huihui Fan,Wenrui Yang,Yang Yang,Youzhen Xiong,Lin Song,Fengkui Zhang
DOI: https://doi.org/10.1007/s00277-022-04952-2
2022-09-24
Annals of Hematology
Abstract:AbstractRabbit antithymocyte globulin (rATG) instead of horse ATG has been used for severe aplastic anemia (SAA) patients in China. This study aimed to investigate the hematologic responses and long-term overall survival (OS) outcomes in SAA patients who received rATG and cyclosporine as first-line immunosuppressive therapy. We analyzed data of 542 SAA patients treated with this therapy between 2005 and 2019. The median age was 20 (range, 2–80) years, and the median follow-up time was 45.5 (range, 0.1–191.4) months. The early mortality rate was 3.9%. The overall response rates (ORRs) were 40.2%, 56.1%, and 62.4% at 3, 6, and 12 months, respectively. The 6- and 12-month ORR of patients treated with 3 mg/kg/d of rATG in 2015–2019 seemed higher than that of patients treated with 3.5–3.75 mg/kg/day in 2005–2014 (60.2% vs. 54.9%, P = 0.30 and 69.9% vs. 60.1%, P = 0.049, respectively). The 10-year cumulative incidences of relapse and clonal evolution were 10.6 ± 2.9% and 7.5 ± 1.5%, respectively. The 10-year OS rate and event-free survival rate were 80.1 ± 2.1% and 75.6 ± 3.7%, respectively. Age, disease severity, treatment periods, and the interval from diagnosis to IST were independent predictors of OS. In conclusion, 3 mg/kg/day rATG is effective as first-line treatment for SAA.
hematology